Direct Ras G12C inhibitors: crossing the rubicon
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Cancer"
DOI: 10.1038/s41416-019-0499-1
Abstract: SummaryDespite its status as the most commonly mutated oncogene in cancer, Ras has long been considered ‘undruggable’. In 2019, we will see the first clinical trial results for direct mutant Ras inhibitors, a result of persistent… read more here.
Keywords: crossing rubicon; direct ras; g12c inhibitors; inhibitors crossing ... See more keywords